Method of treating eye diseases with krill oil
The present invention provides compositions comprising phosphatidylcholine derived compounds carrying an omega-3 fatty acid for use in prophylaxis or therapy, particularly when administered systemically. This invention further relates to a modified krill oil composition enriched in LPC-DHA and LPC-EPA, methods of making and methods of using to treat neurological and ocular disorders.
1. A method for improving, controlling, reducing, or alleviating one or more symptoms and/or signs of an eye disease or condition in a subject in need thereof comprising:
administering to the subject in need thereof an effective amount of a pharmaceutical or nutraceutical formulation comprising a lysophosphatidylcholine (LPC) composition comprising a LPC-compound selected from the group consisting of any one of formulas 1 to 8, and any combination thereof, so that the symptoms of the disease or condition are improved, controlled, reduced, or alleviated:
wherein:
R 1 is OH or —OC(O)(CH 2 ) n CH 3 ;
R 2 is OH or —OC(O)(CH 2 ) n CH 3 ; and
n is 0, 1, or 2;
and wherein the molar ratio of lysoPC-EPA:lysoPC-DHA is in the range of from 1:1 to 5:1; and further wherein
i) the number of moles of lysoPC-EPA is the number of moles 1-lysoPC-EPA plus the number of moles 2-lysoPC-EPA; and
ii) ii) the number of moles of lysoPC-DHA is the number of moles 1-lysoPC-DHA plus the number of moles 2-lysoPC-DHA.
2. The method of claim 1 , wherein R 1 is OH and R 2 is OH.
3. The method according to claim 1 , with the proviso that: if the LPC composition comprises i) a compound according to formula 1, wherein R 2 is OH; and/or ii) a compound according to formula 3, wherein R 1 is OH; then the LPC composition further comprises at least one of the other LPC-compounds referred to in claim 1 .
4. The method of claim 1 , wherein the one or more LPC-compound is:
a compound according to formula 1; and/or a compound according to formula 3; and
a compound according to formula 2; and/or a compound according to formula 4.
5. The method of claim 1 , wherein
R 1 and R 2 are OH; and
the molar ratio of lysoPC-DHA:lysoPC-EPA is from 1:1 to 3:1 wherein i) the number of moles of lysoPC-EPA is the number of moles 1-lysoPC-EPA+the number of moles 2-lysoPC-EPA; and ii) the number of moles of lysoPC-DHA is the number of moles 1-lysoPC-DHA+the number of moles 2-lysoPC-DHA.
6. The method of claim 1 , wherein the disease or condition is dry eye.
7. The method of claim 1 , wherein the disease or condition is a neurodegenerative disease of the eye.
8. The method of claim 7 , wherein the neurodegenerative disease of the eye is selected from the group consisting of age-related macular degeneration, diabetic retinopathy, non-proliferative retinopathy, proliferative retinopathy, diabetic macular edema, retinitis pigmentosa, central vein occlusion, and glaucoma.
9. The method of claim 1 , wherein the administering is by a mode selected from the group consisting of oral administration and intravascular administration.
10. The method of claim 9 , wherein the mode of administration is oral administration.
11. The method of claim 9 , wherein the mode of administration is intravascular administration.
12. The method of claim 1 , wherein the LPC composition in the formulation comprises an amount of total LPC from 10% to 100% by weight of the LPC composition.
13. The method of claim 1 , wherein the LPC composition comprises an additional lipid different from LPC.
14. The method of claim 13 , wherein the additional lipid is selected from the group consisting of triglycerides, free fatty acids, ethyl esters and phospholipids selected from the group consisting of phosphatidylethanolamine and phosphatidylcholine.
15. The method of claim 14 , wherein the LPC composition comprises a predominant amount of the LPC-compound compared to an amount of phosphatidylcholine.
16. The method of claim 1 , wherein the formulation further comprises a component selected from the group consisting of lutein, astaxanthin, zeaxanthin and any combinations thereof.
17. The method of claim 1 , wherein the subject is a mammalian subject.
18. The method of claim 17 , wherein the subject is a human subject.
19. The method of claim 6 , wherein
R 1 and R 2 are OH; and
the molar ratio of lysoPC-EPA:lysoPC-DHA is from 1:1 to 5:1; wherein i) the number of moles of lysoPC-EPA is the number of moles 1-lysoPC-EPA+the number of moles 2-lysoPC-EPA; and ii) the number of moles of lysoPC-DHA is the number of moles 1-lysoPC-DHA+the number of moles 2-lysoPC-DHA.